LIVE

Serial Number

88517411

Owner

I-MAB BIOPHARMA US LIMITED

Attorney

Jacqueline Lesser

First Use Date

Apr 13, 2020

Filing Date

Jul 16, 2019

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

I-MAB BIOPHARMA Trademark

Serial Number: 88517411 • Registration: 6629613

I-MAB BIOPHARMA is a trademark filed by I-MAB BIOPHARMA US LIMITED on July 16, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

I-MAB BIOPHARMA US LIMITED (10 trademarks)

2440 RESEARCH BLVD, SUITE 400
ROCKVILLE, MD 20850

Entity Type: 03

I-MAB (6 trademarks)

George Town KY1-1205 , KY

Entity Type: 03

I-MAB BIOPHARMA CO., LTD (6 trademarks)

RM 802, 8F, 1BLD, WEST TOWER, 88,
SHANGHAI 201210 , CN

Entity Type: 03

Legal Representation

Attorney of Record

Jacqueline Lesser

141 trademarks filed View all →

Correspondence Address

Jacqueline Lesser Ice Miller LLP

1735 Market Street

Philadelphia, PA 19103

United States

Trademark Details

Filing Date

July 16, 2019

Registration Date

January 25, 2022

First Use Anywhere

April 13, 2020

First Use in Commerce

April 28, 2020

Published for Opposition

September 7, 2021

Goods & Services

Monoclonal antibodies for use in disease testing; biological preparations for the treatment of cancer, tumor suppressing agents, anti-cancer preparations, and pharmaceutical preparations for the treatment of immune system related diseases and disorders, all comprising monoclonal antibodies

Biomedical research services; conducting early evaluations in the field of new pharmaceuticals; quality control of goods and services; product quality testing; pharmaceutical product evaluation; biological research; conducting clinical trials for others that feature or contain monoclonal antibodies; research and development services in the field of antibodies

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED

Dec 1, 2025 TCCA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Dec 1, 2025 ARAA

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Dec 1, 2025 REAP

TEAS CHANGE OF CORRESPONDENCE RECEIVED

Apr 16, 2025 TCCA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Apr 16, 2025 ARAA

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Apr 16, 2025 REAP

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

Apr 16, 2025 CHAN

TEAS CHANGE OF OWNER ADDRESS RECEIVED

Apr 16, 2025 COAR

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Dec 25, 2024 ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

May 17, 2023 ASGN

REGISTERED-PRINCIPAL REGISTER

Jan 25, 2022 R.PR

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Dec 24, 2021 SUNA

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Dec 23, 2021 CNPR

EXAMINER'S AMENDMENT ENTERED

Dec 23, 2021 XAEC

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Dec 23, 2021 GNEN

EXAMINERS AMENDMENT E-MAILED

Dec 23, 2021 GNEA

SU-EXAMINER'S AMENDMENT WRITTEN

Dec 23, 2021 SNEA

STATEMENT OF USE PROCESSING COMPLETE

Dec 21, 2021 SUPC

CASE ASSIGNED TO INTENT TO USE PARALEGAL

Dec 13, 2021 AITU

USE AMENDMENT FILED

Nov 12, 2021 IUAF

TEAS STATEMENT OF USE RECEIVED

Nov 12, 2021 EISU

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Nov 2, 2021 NOAM

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Sep 7, 2021 NPUB

PUBLISHED FOR OPPOSITION

Sep 7, 2021 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Aug 18, 2021 NONP

ASSIGNED TO LIE

Aug 2, 2021 ALIE

APPROVED FOR PUB - PRINCIPAL REGISTER

Aug 2, 2021 CNSA

TEAS/EMAIL CORRESPONDENCE ENTERED

Jul 30, 2021 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jul 29, 2021 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Jul 29, 2021 TROA

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Jul 1, 2021 GNRN

NON-FINAL ACTION E-MAILED

Jul 1, 2021 GNRT

NON-FINAL ACTION WRITTEN

Jul 1, 2021 CNRT

TEAS/EMAIL CORRESPONDENCE ENTERED

Jun 4, 2021 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jun 3, 2021 CRFA

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

Jun 3, 2021 ERSI

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

Apr 13, 2021 RCSC

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED

Oct 13, 2020 RCSC

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Apr 9, 2020 GNS3

LETTER OF SUSPENSION E-MAILED

Apr 9, 2020 GNSL

SUSPENSION LETTER WRITTEN

Apr 9, 2020 CNSL

TEAS/EMAIL CORRESPONDENCE ENTERED

Mar 11, 2020 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Mar 10, 2020 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Mar 10, 2020 TROA

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

Oct 24, 2019 CHAN

TEAS CHANGE OF OWNER ADDRESS RECEIVED

Oct 24, 2019 COAR

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Sep 12, 2019 GNRN

NON-FINAL ACTION E-MAILED

Sep 12, 2019 GNRT

NON-FINAL ACTION WRITTEN

Sep 12, 2019 CNRT

ASSIGNED TO EXAMINER

Sep 10, 2019 DOCK

NOTICE OF DESIGN SEARCH CODE E-MAILED

Jul 24, 2019 MDSC

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Jul 23, 2019 NWOS

NEW APPLICATION ENTERED

Jul 19, 2019 NWAP

Related Trademarks

More from this Owner

I-MAB BIOPHARMA

Serial #88516939

More in Same Class

SMARTPQQ

Serial #88516778